We provide you with 20 years of free, institutional-grade data for NTLA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NTLA. Explore the full financial landscape of NTLA stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-07 | 1652130 | NTLA | 10-Q | Url |
| 2025-05-08 | 1652130 | NTLA | 10-Q | Url |
| 2025-02-27 | 1652130 | NTLA | 10-K | Url |
| 2024-11-07 | 1652130 | NTLA | 10-Q | Url |
| 2024-08-08 | 1652130 | NTLA | 10-Q | Url |
| 2024-05-09 | 1652130 | NTLA | 10-Q | Url |
| 2024-02-22 | 1652130 | NTLA | 10-K | Url |
| 2023-11-09 | 1652130 | NTLA | 10-Q | Url |
| 2023-08-03 | 1652130 | NTLA | 10-Q | Url |
| 2023-05-04 | 1652130 | NTLA | 10-Q | Url |
| 2023-02-23 | 1652130 | NTLA | 10-K | Url |
| 2022-11-03 | 1652130 | NTLA | 10-Q | Url |
| 2022-08-04 | 1652130 | NTLA | 10-Q | Url |
| 2022-05-05 | 1652130 | NTLA | 10-Q | Url |
| 2022-02-24 | 1652130 | NTLA | 10-K | Url |
| 2021-11-04 | 1652130 | NTLA | 10-Q | Url |
| 2021-08-05 | 1652130 | NTLA | 10-Q | Url |
| 2021-05-06 | 1652130 | NTLA | 10-Q | Url |
| 2021-02-26 | 1652130 | NTLA | 10-K | Url |
| 2020-11-05 | 1652130 | NTLA | 10-Q | Url |
| 2020-08-06 | 1652130 | NTLA | 10-Q | Url |
| 2020-05-07 | 1652130 | NTLA | 10-Q | Url |
| 2020-02-27 | 1652130 | NTLA | 10-K | Url |
| 2019-10-31 | 1652130 | NTLA | 10-Q | Url |
| 2019-08-01 | 1652130 | NTLA | 10-Q | Url |
| 2019-05-02 | 1652130 | NTLA | 10-Q | Url |
| 2019-02-27 | 1652130 | NTLA | 10-K | Url |
| 2018-10-31 | 1652130 | NTLA | 10-Q | Url |
| 2018-08-01 | 1652130 | NTLA | 10-Q | Url |
| 2018-05-01 | 1652130 | NTLA | 10-Q | Url |
| 2018-03-14 | 1652130 | NTLA | 10-K | Url |
| 2017-10-31 | 1652130 | NTLA | 10-Q | Url |
| 2017-08-01 | 1652130 | NTLA | 10-Q | Url |
| 2017-05-02 | 1652130 | NTLA | 10-Q | Url |
| 2017-03-14 | 1652130 | NTLA | 10-K | Url |
| 2016-11-01 | 1652130 | NTLA | 10-Q | Url |
| 2016-08-04 | 1652130 | NTLA | 10-Q | Url |
| 2016-06-03 | 1652130 | NTLA | 10-Q | Url |
| 2016-04-11 | 1652130 | NTLA | S-1 | Url |
Intellia Therapeutics, Inc(NASDAQ:NTLA) 
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which i...
Website: http://www.intelliatx.com
Founded: 2014
Full Time Employees: 270
CEO: John Leonard
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about NTLA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.